Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sunshine Provision Retained In Opioids Bill Compromise

Executive Summary

Congressional negotiators knitting together US Senate and House versions of opioids legislation retained a “sunshine” provision opposed by industry that would expand the types of health-care professionals for whom device and drug manufacturers must report to the federal Open Payments database.


Related Content

President Signs Opioids Bill Calling For Alternative Tech, More Pain-Control Research
Device Industry Champion Erik Paulsen In Tough Election Fight To Retain House Seat
Expanded Sunshine Provisions Will Burden Industry, Yield Little, Attorneys Say
Payment 'Sunshine' Requirements Would Expand For Industry Under Senate-Passed Opioid Bill





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts